TMCnet News
Epogen (epoetin alfa; Amgen/Kyowa Hakko Kirin/Johnson & Johnson) Drug Analysis 2018 - ResearchAndMarkets.comThe "Drug Analysis: Epogen" drug pipelines has been added to ResearchAndMarkets.com's offering. Epogen (epoetin alfa; Amgen/Kyowa Hakko Kirin/Johnson & Johnson) is an erythropoiesis-stimulating agent administered by intravenous or subcutaneous injection, and is indicated for the treatment of anemia in chronic kidney disease and chemotherapy-induced anemia. The drug consists of recombinant human erythropoietin and targets the erythropoietin receptor, initiating the same pathway as native erythropoietin and triggering increased blood production in bone marrow. Key Topics Covered: List of Figures Figure 1: Epogen for anemia in chronic kidney disease - SWOT analysis Figure 2: Drug assesment summary of Epogen for anemia in chronic kidney disease Figure 3: Drug assessment summary of Epogen for anemia in chronic kidney disease Figure 4: Epogen sales for anemia in chronic kidney disease across the US, Japan, and major EU markets, by country, 2015-24 Figure 5: Epogen for chemotherapy-induced anemia - SWOT analysis Figure 6: Drug assessment summary of Epogen in chemotherapy-induced anemia Figure 7: Drug assessment summary of Epogen in chemotherapy-induced anemia List of Tables Table 1: Epogen drug profile Table 2: Epogen pivotal trial data in anemia in chronic kidney disease Table 3: Epogen other late-phase trial data in anemia in chronic kidney disease Table 4: Epogen sales for anemia in chronic kidney disease across the US, Japan, and major EU markets, by country ($m), 2015-24 Table 5: Epogen drug profile Table 6: Epogen pivotal trial data in chemotherapy-induced anemia Table 7: Epogen ongoing late-phase clinical trial in chemotherapy-induced anemia For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/jn5hnv/epogen_epoetin?w=4 View source version on businesswire.com: http://www.businesswire.com/news/home/20180219005526/en/ |
